# A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke

Study · id `cardio:ct-nct05301712` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05301712](<https://clinicaltrials.gov/study/NCT05301712>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05301712

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 446 participants.

## Technical summary

Registry record NCT05301712. Randomized; quadruple masking; primary purpose treatment. Start 2018-08-07 (actual); primary completion 2022-10-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 446 participants (enrolled count; ClinicalTrials.gov record NCT05301712, source copy `cardio:ctgov-nct05301712-2023-08-14`, retrieved 2026-10-26)
- Started: 2018-08-07 (actual) (ClinicalTrials.gov record NCT05301712, source copy `cardio:ctgov-nct05301712-2023-08-14`, retrieved 2026-10-26)
- Primary completion: 2022-10-25 (actual) (ClinicalTrials.gov record NCT05301712, source copy `cardio:ctgov-nct05301712-2023-08-14`, retrieved 2026-10-26)
- Completion: 2023-07-10 (actual) (ClinicalTrials.gov record NCT05301712, source copy `cardio:ctgov-nct05301712-2023-08-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05301712, source copy `cardio:ctgov-nct05301712-2023-08-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05301712-2023-08-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke
- Condition: Stroke, Acute
- Intervention (Drug): Naloxone hydrochloride 5.0mg/5ml
- Intervention (Drug): Sodium Chloride 45mg/5ml
- Lead sponsor: Samjin Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Samjin Pharmaceutical Co., Ltd. (`cardio:org-samjin-pharmaceutical-co-ltd`)

## Provenance

Content hash: 0fe8d923dfa6a97db6e06d2e93d75951d381631e768626d06ad6a8245c3cfb2c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
